No Data
Haichuang Pharmaceutical (688302.SH): The first subject has been enrolled in the clinical trial of the oral PROTAC drug HP568 in China.
On January 9, Gelonghui reported that Haichuang Pharmaceutical (688302.SH) announced that the clinical trial of HP568 tablets, developed independently by the company for the treatment of estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer (ER+/HER2- advanced breast cancer), recently completed the enrollment of its first subject. HP568 tablets are an orally administered medication developed by the company.
Hai Chuang Pharmaceutical (688302.SH): The clinical trial application for HP568 tablets for the treatment of ER+/HER2- advanced breast cancer has been approved by the USA FDA.
Haichuang Pharmaceutical (688302.SH) announced that the company has received approval from the USA Food and Drug Administration (referred to as "FDA"...)
Third Quarter Report 2024
Hinova Pharmaceuticals Gets Regulatory Approval to Conduct Breast Cancer Clinical Trial
Haisco Pharmaceutical (688302.SH): Yingchuang Power has cumulatively reduced its shareholding by 1%.
GeLongHui, October 14th | HaiChuang Pharmaceutical (688302.SH) announced that the company recently received a notice from YingChuang Power regarding the expiration of the shareholding reduction plan period and the results of the reduction. As of October 14, 2024, the current shareholding reduction plan period has expired. During the implementation of this shareholding reduction plan, YingChuang Power has cumulatively reduced 990,150 shares of the company's stock, accounting for 1.00% of the total share capital of the company.
Hinova Pharmaceuticals Inc. (SHSE:688302) Surges 23%; Individual Investors Who Own 33% Shares Profited Along With Institutions
No Data